Clinical trials: Primary Central Nervous System Lymphoma
Central Nervous System Lymphoma
Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
This is a single-arm and open-label study to explore X+MTX+Ritu (ATG-010, Methotrexate, Rituximab) regimen in Relapse refractory PCNSL patients. Approximately 30 patients will be enrolled in the study.
- Trial name
- NCT05698147
- Testing
- Selinexor, Rituximab, Methotrexate
- Where
- 5 sites in China
- Volunteers
- 30 people
- Sponsor
- Tong Chen, MD
Primary Central Nervous System Lymphoma, PCNSL
Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma
The purpose of the study is to test the efficacy and tolerability of a combination treatment of methotrexate, ibrutinib, and temozolomide (MIT regimen) in treating patients who have newly-diagnosed primary CNS lymphoma.
- Conditions
- Primary Central Nervous System Lymphoma, PCNSL, Non Hodgkin Lymphoma
- Trial name
- NCT04514393
- Testing
- Methotrexate, Ibrutinib, Temozolomide
- Where
- 3 sites in China
- Volunteers
- 33 people
- Sponsor
- Huiqiang Huang
Lymphoma
Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma
RATIONALE: Drugs used in chemotherapy, such as methotrexate, cyclophosphamide, etoposide phosphate, dexamethasone, and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- Protocol-B (NCT00074178)
- Testing
- filgrastim, pegfilgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- OHSU Knight Cancer Institute
Brain and Central Nervous System Tumors, Lymphoma
Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well pemetrexed disodium works in treating patients with…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer
- Trial name
- NCT00276783
- Testing
- pemetrexed
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Northwestern University
Primary Central Nervous System Lymphoma
A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL
This is a single arm, single center, open label pilot study of Orelabrutinib combined with Rituximab, high-dose (HD) Methotrexate and Dexamethasone in newly-diagnosed primary central nervous system lymphpoma (PCNSL).
- Trial name
- ORMD2021 (NCT05036577)
- Testing
- Orelabrutinib, Rituximab, Methotrexate (MTX)
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Huashan Hospital
Primary Central Nervous System Diffusing Large Cell Lymphoma
The Role of Surgical Resection AND Stereotactic Radiosurgery in Primary Central Nervous System -Diffuse Large B Cell Lymphoma
The objective of this observational study is to understand the long-term impact of surgery and gamma knife treatment on primary central diffuse large B-cell lymphoma.
- Trial name
- NCT07007611
- Volunteers
- 76 people
- Sponsor
- jiahong Deng
Relapsed/Refractory Primary Central Nervous System Lymphoma
A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma
This study is a prospective, single-arm, open label, Phase Ib/II clinical study to evaluate the safety and efficacy of selinexor in combination with temozolomide and anti-PD-1 monoclonal antibody in patients with…
- Trial name
- NCT06556199
- Testing
- Selinexor, Temozolomide, Anti-PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Primary CNS Lymphoma
Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma
This phase I trial evaluates the feasibility of using hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing patients with primary central nervous system lymphoma.
- Trial name
- NCT04656431
- Testing
- Hyperpolarized pyruvate (13C), Magnetic resonance imaging (MRI)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- James Rubenstein
Primary Central Nervous System Lymphoma
[18F]-Fludarabine PET/MRI in Primary Central Nervous System Lymphoma
Primary central nervous system (CNS) lymphomas represent 5% of primary brain tumors. More than 90% of them are diffuse large B-cell lymphomas.
- Trial name
- FLUDALOC (NCT05390814)
- Testing
- PET-MRI
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
B-Cell Lymphoma Originating in the CNS
The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma
The primary purpose of the study will be testing the dosing of temozolomide to find the target dose that a person can tolerate. The other part of the study will be determining how helpful it can be to CNS lymphoma patients by…
- Trial name
- DRBEAT (NCT01235793)
- Testing
- Temozolomide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cedars-Sinai Medical Center
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well vemurafenib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with BRAF V600 mutations that have spread to other places in the body…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Ependymoma
- Trial name
- NCT03220035
- Testing
- Laboratory Biomarker Analysis, Vemurafenib
- Where
- 116 sites in United States, Puerto Rico
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma
The purpose of this study is to find out what effects (good and/or bad) treatment with chemotherapy and stem cell transplant compared with chemotherapy alone will have on primary CNS B-cell lymphoma.
- Trial name
- NCT01511562
- Testing
- carmustine, cytarabine, etoposide
- Where
- 126 sites in United States
- Volunteers
- 113 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Mucopolysaccharidosis I, Mucopolysaccharidosis VI
Human Placental-Derived Stem Cell Transplantation
The purpose of this clinical trial is to investigate the safety of human placental-derived stem cells (HPDSC) given in conjunction with umbilical cord blood (UCB) stem cells in patients with various malignant or nonmalignant…
- Conditions
- Mucopolysaccharidosis I, Mucopolysaccharidosis VI, Adrenoleukodystrophy, Niemann-Pick Disease
- Trial name
- HPDSC (NCT01586455)
- Testing
- Human Placental Derived Stem Cell
- Where
- 3 sites in United States
- Volunteers
- 43 people
- Sponsor
- New York Medical College
CNS Lymphoma
GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma
The STAR CNS trial is a 3-part study, comprising a phase 1b dose escalation, dose expansion, and a phase 2, to assess the safety, tolerability, dose-limiting toxicity(ies), maximum tolerated dose, and/or optimal biological dose…
- Trial name
- STAR CNS (NCT05242146)
- Testing
- GB5121
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 12 people
- Sponsor
- GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Primary Central Nervous System Lymphoma
Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma
To explore PFS, ORR (CR/CRu+PR), OS and side effects of piamprizumab combined with RMA in newly diagnosed PCNSL, so as to clarify the value of piamprizumab combined with RMA in the first-line treatment of PCNSL patients, and to…
- Trial name
- NCT05347641
- Testing
- Penpulimab
- Volunteers
- 23 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University